Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
10 SEK | -0.99% | +3.09% | -10.87% |
06/02 | Transcript : Boule Diagnostics AB, 2023 Earnings Call, Feb 06, 2024 | |
06/02 | Transcript : Boule Diagnostics AB, 2023 Earnings Call, Feb 06, 2024 |
Strengths
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- With regards to fundamentals, the enterprise value to sales ratio is at 0.8 for the current period. Therefore, the company is undervalued.
- The company's share price in relation to its net book value makes it look relatively cheap.
Weaknesses
- For the past year, analysts have significantly revised downwards their profit estimates.
- Over the past four months, analysts' average price target has been revised downwards significantly.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-10.87% | 35.61M | B- | ||
+7.62% | 218B | B | ||
+6.70% | 183B | B- | ||
+11.94% | 134B | B- | ||
+24.60% | 106B | A- | ||
-2.66% | 61.12B | A- | ||
+4.81% | 50.89B | B+ | ||
+11.55% | 51.26B | B+ | ||
-1.09% | 40.3B | A | ||
+26.82% | 32.05B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- BOUL Stock
- Ratings Boule Diagnostics AB